Biorestorative Therapies, Inc. (NASDAQ:BRTX) Shares Shorted: Short Interest Up 146.3% in October

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 36,404 shares, an increase of 146.3% from the October 15th total of 14,778 shares. Based on an average daily volume of 38,359 shares, the short-interest ratio is currently 0.9 days. Currently, 3.1% of the shares of the stock are sold short.

Biorestorative Therapies Price Performance

NASDAQ BRTX traded down $0.03 during mid-day trading on Friday, hitting $1.48. The stock had a trading volume of 5,997 shares, compared to its average volume of 292,548. The firm’s 50 day moving average is $2.03 and its 200 day moving average is $5.51. Biorestorative Therapies has a twelve month low of $1.28 and a twelve month high of $28.99. The stock has a market capitalization of $2.04 million, a price-to-earnings ratio of -0.07 and a beta of 0.93.

Analyst Ratings Changes

BRTX has been the topic of a number of research reports. Maxim Group lowered shares of Biorestorative Therapies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday, August 24th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Biorestorative Therapies has a consensus rating of “Reduce”.

Biorestorative Therapies Company Profile

BioRestorative Therapies, Inc. is a biotechnology company focused on developing regenerative medicine products using cell and tissue-based technologies. The company’s programs are intended to address conditions for which existing treatment options may be limited, including musculoskeletal and metabolic disorders. Its lead product candidate, BRTX-100, is an autologous cell therapy developed from a patient’s own bone marrow and designed to treat painful lumbar disc disease, including chronic lower-back pain associated with degenerated discs.